```html

Junctional Tachycardia (AVNRT) – Complete Medical Guide

Overview

Junctional tachycardia, most commonly referring to atrioventricular nodal re‑entrant tachycardia (AVNRT), is a type of supraventricular arrhythmia in which an abnormal electrical circuit inside or near the atrioventricular (AV) node causes the heart to beat rapidly—typically 150–250 beats per minute (bpm). The term “junctional” denotes that the impulse originates from the area where the atria and ventricles meet (the AV junction).

• Who it affects: AVNRT is the single most frequent form of paroxysmal supraventricular tachycardia (PSVT). It is seen in both sexes but is slightly more common in women (≈55‑60%).
• Age distribution: The condition often appears in adolescents and young adults (15‑40 years) but can be diagnosed at any age, including in children and the elderly.
• Prevalence: PSVT accounts for 2–3 % of all emergency‑department visits for chest pain or palpitations. AVNRT makes up roughly 60 % of these cases, translating to an estimated 300 000–400 000 new diagnoses in the United States each year (American Heart Association, 2022).

Symptoms

Symptoms are usually abrupt in onset and may last from a few seconds to several hours. The intensity can vary with activity, stress, caffeine, or hormonal changes.

• Palpitations: A rapid, “fluttering” or “ racing” sensation in the chest.
• Sudden onset/offset: The heart rate spikes abruptly and returns to normal just as quickly.
• Chest discomfort: Tightness, pressure, or a vague ache; rarely mimics angina.
• Shortness of breath (dyspnea): Especially during or after an episode.
• Dizziness or light‑headedness: Caused by transiently reduced cerebral perfusion.
• Syncope (fainting): Uncommon but possible if the rate is extremely high or if underlying heart disease exists.
• Fatigue or weakness: After repeated episodes, patients may feel unusually tired.
• Headache: A throbbing headache can follow prolonged tachycardia.
• Feeling of anxiety or panic: The rapid heartbeat often triggers a stress response.
• Exercise intolerance: Difficulty completing usual physical activities.

Causes and Risk Factors

Pathophysiology

AVNRT arises from a re‑entrant circuit within the AV node, which typically has two pathways:

1. Fast pathway: Conducts impulses quickly but has a longer refractory period.
2. Slow pathway: Conducts more slowly but recovers faster.

A premature atrial beat can travel down the slow pathway while the fast pathway is still refractory. Once the impulse reaches the lower part of the node, it can travel retro‑grade up the fast pathway, creating a loop that repeats many times per second—hence the tachycardia.

Risk Factors

• Age: Young adults and teenagers are most commonly affected.
• Female sex: Slightly higher incidence in women.
• Structural heart disease: Congenital abnormalities, cardiomyopathy, or prior cardiac surgery increase risk.
• Electrolyte disturbances: Low potassium or magnesium can precipitate arrhythmias.
• Stimulants: Caffeine, nicotine, alcohol, illicit drugs (e.g., cocaine, methamphetamine).
• Medications: Decongestants, certain asthma inhalers, or over‑the‑counter cold remedies containing pseudoephedrine.
• Hormonal changes: Pregnancy or menstrual cycle fluctuations may exacerbate episodes.
• Stress and autonomic tone: Emotional stress, anxiety, or extreme exercise can trigger episodes.

Diagnosis

Because AVNRT mimics other causes of rapid heart rates, a systematic approach is essential.

Clinical Evaluation

• History: Typical description of sudden palpitations, duration, precipitating factors, and any associated symptoms.
• Physical exam: May reveal a regular, narrow‑complex tachycardia (QRS ≤ 120 ms) with a rapid rate (150‑250 bpm). No murmurs or signs of heart failure are usually present.

Electrocardiogram (ECG)

The definitive test. During an episode, the ECG shows a regular, narrow‑complex tachycardia with retrograde P‑waves (often hidden in or shortly after the QRS). In the inter‑episode (baseline) ECG, the rhythm is usually normal.

Holter Monitor or Event Recorder

Continuous (24‑48 h) or patient‑triggered recording devices capture sporadic episodes that may not occur during a clinic visit. Sensitivity for detecting AVNRT is > 90 % when the device is worn for ≥ 48 h.

Electrophysiology Study (EPS)

Invasive testing performed in an electrophysiology lab. Catheters are placed via veins to map the electrical pathways. EPS confirms the diagnosis, differentiates AVNRT from other SVTs, and often allows for immediate treatment (catheter ablation).

Other Tests (if indicated)

• Blood tests: electrolytes, thyroid‑stimulating hormone (TSH) to rule out hyperthyroidism.
• Echocardiogram: evaluates structural heart disease that could modify management.

Treatment Options

Treatment is individualized based on frequency of episodes, symptom severity, comorbidities, and patient preference.

Acute Termination of an Episode

1. Vagal maneuvers: Simple techniques that increase vagal tone and can break the re‑entrant circuit.
   • Valsalva maneuver (blow into a syringe for 15 seconds).
   • Carotid sinus massage (performed only by trained professionals).
2. Pharmacologic therapy: If vagal maneuvers fail, clinicians may give:
   • Adenosine 6 mg rapid IV push; may repeat 12 mg if needed. Works in > 95 % of AVNRT cases (Mayo Clinic, 2023).
   • Beta‑blockers (e.g., metoprolol 5 mg IV) or non‑dihydropyridine calcium‑channel blockers (verapamil 2.5 mg IV) for patients who cannot receive adenosine.

Long‑Term Management

• Medications (for patients with frequent episodes or who are not candidates for ablation):
  • Beta‑blockers (atenolol, propranolol) – reduce AV nodal conduction.
  • Calcium‑channel blockers (verapamil, diltiazem) – especially useful in patients with asthma or COPD where beta‑blockers are contraindicated.
  • Anti‑arrhythmic drugs (flecainide, propafenone) – reserved for refractory cases due to potential pro‑arrhythmic risk.
• Catheter Ablation:

  Radiofrequency or cryo‑ablation of the slow pathway is the treatment of choice for symptomatic AVNRT. Success rates exceed 98 % with a <1 % risk of serious complications (Cleveland Clinic, 2022). Most patients can return to normal activities within 1‑2 days.

• Lifestyle Modifications:
  • Limit caffeine, alcohol, and nicotine.
  • Maintain adequate hydration and electrolytes.
  • Practice regular aerobic exercise (unless contraindicated) to improve autonomic balance.
  • Stress‑reduction techniques – yoga, mindfulness, biofeedback.

Living with Junctional Tachycardia (AVNRT)

While AVNRT is not usually life‑threatening, it can impact quality of life. Below are practical tips for day‑to‑day management.

Self‑Monitoring

• Keep a symptom diary: record date, time, duration, triggers, and heart‑rate (if known).
• Consider a smartwatch or portable ECG device that can capture rhythm strips for review by your physician.

When to Use Vagal Maneuvers

Learn the Valsalva technique and practice it at home. If an episode lasts > 30 seconds without relief, seek medical help.

Medication Adherence

Take prescribed drugs exactly as directed. Do not abruptly stop beta‑blockers without consulting your doctor, as withdrawal can provoke rebound tachycardia.

Regular Follow‑Up

Schedule an annual cardiology review or sooner if episodes become more frequent, longer, or are associated with new symptoms (e.g., chest pain, syncope).

Exercise & Activity

• Most patients can engage in moderate‑intensity exercise once symptoms are controlled.
• Avoid extreme endurance events until you have clearance from an electrophysiologist.

Pregnancy Considerations

AVNRT often improves during pregnancy, but if episodes become troublesome, beta‑blockers such as labetalol are commonly used because of their safety profile (ACOG, 2021).

Prevention

Because the underlying anatomical substrate cannot be eliminated without an ablation, prevention focuses on reducing triggers.

• Limit stimulant intake (caffeine < 200 mg/day, no energy drinks).
• Quit smoking and reduce alcohol consumption.
• Correct electrolyte imbalances – especially potassium (> 4 mmol/L) and magnesium (> 2 mg/dL).
• Manage thyroid disease, anemia, and sleep apnea, all of which can precipitate tachyarrhythmias.
• Adopt regular stress‑management practices (meditation, deep‑breathing exercises).

Complications

Although AVNRT is generally benign, untreated or recurrent episodes may lead to:

• Heart failure: Persistent tachycardia can cause tachy‑cardiomyopathy, presenting as reduced ejection fraction.
• Syncope or injury: Due to sudden loss of consciousness during an episode.
• Thromboembolic events: Rare, but atrial stasis during rapid rates may increase clot risk, especially in patients with underlying atrial enlargement.
• Psychological impact: Anxiety or panic disorder secondary to fear of episodes.

When to Seek Emergency Care

---

Sources: Mayo Clinic (2023); American Heart Association (2022); Cleveland Clinic (2022); American College of Obstetricians and Gynecologists (2021); CDC & NIH guidelines on arrhythmia management; peer‑reviewed electrophysiology studies, Heart Rhythm journal, 2021‑2023.

```